Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy

Clinical Research in Cardiology

Volumn 96, Issue 12, 2007, Pages 856-863

  Seggewiss, Hubert ^a   Rigopoulos, Angelos ^b   Welge, Dirk ^c   Ziemssen, Peer ^a   Faber, Lothar ^c  

^a Leopoldina Krankenhaus   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Hypertrophic obstructive cardiomyopathy; Left ventricular remodeling; Percutaneous septal ablation; Survival

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; VERAPAMIL;

ADULT; ARTICLE; CATHETER ABLATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE WALL; HOLTER MONITORING; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE RESECTION; PACEMAKER; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL SEPTUM MYOCARDIAL ABLATION; STROKE; TREATMENT OUTCOME; VALSALVA MANEUVER;

CARDIOMYOPATHY, HYPERTROPHIC; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; ECHOCARDIOGRAPHY, DOPPLER; ETHANOL; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART SEPTUM; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; SOLVENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 36448992594     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0579-8     Document Type: Article

References (31)

1. Wigle ED, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92:1680- 1692
2. Maron BJ, McKenna WJ, Danielson GK et al (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687-1713
3. Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775-785
4. Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ (1995) Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 92:II122-127
5. Schulte HD, Gramsch-Zabel H, Schwartzkopff B (1995) Hypertrophe obstruktive Kardiomyopathie: Chirurgische Behandlung. Hypertrophic obstructive cardiomyopathy: surgical treatment. Schweiz Med Wochenschr 125:1940-1949
6. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM (1995) Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg 110:195-206 (discussion 206-208)
7. Woo A, Williams WG, Choi R et al (2005) Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111:2033-2041
8. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS (1999) Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 99:2927-2933
9. Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211-214
10. Gleichmann U, Seggewiss H, Faber L, Fassbender D, Schmidt HK, Strick S (1996) Kathetertherapie der hypertrophen obstruktiven Kardiomyopathie. Catheter treatment of hypertrophic obstructive cardiomyopathy. Dtsch Med Wochenschr 121:679-685
11. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 31:252-258
12. Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98:2415-2421
13. Knight C, Kurbaan AS, Seggewiss H et al (1997) Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 95:2075-2081
14. Nagueh SF, Lakkis NM, He ZX et al (1998) Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 32:225-229
15. Gietzen FH, Leuner CJ, Raute-Kreinsen U et al (1999) Acute and longterm results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342-1354
16. Sahn D, De Maria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. The committee on M-mode standardization of the American Society of Echocardiography. Circulation 58:1072-1083
17. Pollick C, Rakowski H, Wigle ED (1984) Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient. Circulation 69:43-49
18. Seggewiss H (2001) Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep 3:160-166
19. Elliott PM, Poloniecki J, Dickie S et al (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36:2212-2218
20. Qin JX, Shiota T, Lever HM et al (2001) Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 38:1994-2000
21. Firoozi S, Elliott PM, Sharma S et al (2002) Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 23:1617-1624
22. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd (2000) Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 36:852-855
23. Faber L, Meissner A, Ziemssen P, Seggewiss H (2000) Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 83:326-331
24. Schulz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG (2000) The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation 101:1764-1766
25. Curtius JM, Stoecker J, Loesse B, Welslau R, Scholz D (1989) Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment. Cardiology 76:255-263
26. Rivera S, Sitges M, Azqueta M et al (2003) Left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy treated with percutaneous alcohol septal ablation: an echocardiographic study. Rev Esp Cardiol 56:1174-1181
27. Maron BJ (1999) New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. Eur Heart J 20:1292-1294
28. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ (1990) Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 82:1995-2002
29. Raute-Kreinsen U (2003) Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy. Pathol Res Pract 199:121-127
30. Maron MS, Olivotto I, Betocchi S et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295-303
31. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of haemodynamic and clinical response. Clin Res Cardiol (in press)